I share my portfolio, thoughts, and equity ideas via Substack; a multi-strategy fund specializing in L/S, M&A Arb, Special Situations, and event-driven ideas.
www.cedargrovecm.com
$REAL crossed the 3x line, and we're pleased by the results.
$KITS.TO announced a record-breaking sales week
$SNWV recovering nicely from CMS changes
$LNSR arb is iffy
Find it below
www.cedargroveresearch.com/p/bunch-of-q...
$REAL crossed the 3x line, and we're pleased by the results.
$KITS.TO announced a record-breaking sales week
$SNWV recovering nicely from CMS changes
$LNSR arb is iffy
Find it below
www.cedargroveresearch.com/p/bunch-of-q...
To showcase our original work on why there was such a mispricing, I've removed the paywall
Access it with your email and you'll be able to read the whole thing. Onto the next one!
www.cedargroveresearch.com/p/the-realre...
To showcase our original work on why there was such a mispricing, I've removed the paywall
Access it with your email and you'll be able to read the whole thing. Onto the next one!
www.cedargroveresearch.com/p/the-realre...
With how well the company is executing, it might end up being a 3x for us by the end of the year.
Once again, appreciate all those who've supported our work.
With how well the company is executing, it might end up being a 3x for us by the end of the year.
Once again, appreciate all those who've supported our work.
Lifts GMV, sales, and EBITDA guide for FY'25. Crazy how people still don't understand the tailwinds here
Inflection in profitability will only expand with continued operating leverage
Congrats to those who played this; +11% rn
Lifts GMV, sales, and EBITDA guide for FY'25. Crazy how people still don't understand the tailwinds here
Inflection in profitability will only expand with continued operating leverage
Congrats to those who played this; +11% rn
- Clinical subs roll off less than feared
- Overall subs better than expected
- Rev beat on estimates
- Adj. EBITDA beat
- Guidance narrowed to top of range for rev + AE
- Cash handsomely at $170M; +$17M Q/Q
$WW +7% in PM
- Clinical subs roll off less than feared
- Overall subs better than expected
- Rev beat on estimates
- Adj. EBITDA beat
- Guidance narrowed to top of range for rev + AE
- Cash handsomely at $170M; +$17M Q/Q
$WW +7% in PM
An update from $FTC or $ALC?
An update from $FTC or $ALC?
+23% off the lows
- blew past sales estimates
- profitable on an adjusted basis
- >2,000 unique patients
One of the many companies we've profiled this year to cross the 100% return mark
Very excited to see where it continues to go from here
Check our work below
+23% off the lows
- blew past sales estimates
- profitable on an adjusted basis
- >2,000 unique patients
One of the many companies we've profiled this year to cross the 100% return mark
Very excited to see where it continues to go from here
Check our work below
- blew past sales estimates
- profitable on an adjusted basis
- >2,000 unique patients
One of the many companies we've profiled this year to cross the 100% return mark
Very excited to see where it continues to go from here
Check our work below
The value is in the credit agreement and assuming no upside to projections or the multiple, we're looking at >$25/share of equity value.
See our credit agreement explanation and math below. 1/2
The value is in the credit agreement and assuming no upside to projections or the multiple, we're looking at >$25/share of equity value.
See our credit agreement explanation and math below. 1/2
Nothing bad seems to stick to this stock, but we outlined 3 potential scenarios that might.
Find it all below.
www.cedargroveresearch.com/p/hims-andre...
Nothing bad seems to stick to this stock, but we outlined 3 potential scenarios that might.
Find it all below.
www.cedargroveresearch.com/p/hims-andre...
The "value" is from their terms in their credit agreement.
You can keep all assumptions the same and the equity value is worth >2x what it is now.
That's assuming nothing incremental. That's the play.
Have a look below for the key points and link to the report.
cedargrovecapital.substack.com/p/special-si...
The "value" is from their terms in their credit agreement.
You can keep all assumptions the same and the equity value is worth >2x what it is now.
That's assuming nothing incremental. That's the play.
It's all pixie dust. Hindsight 20/20
It's all pixie dust. Hindsight 20/20
I know how it feels to want to read research but not be able to afford the full price.
Use the link below to get access. A school email is required!
www.cedargrovecm.com/1be24f84
I know how it feels to want to read research but not be able to afford the full price.
Use the link below to get access. A school email is required!
www.cedargrovecm.com/1be24f84
Sometimes...it's just paper value.
Sometimes...it's just paper value.
I'm sound asleep knowing my teddy bear company, Build-a-Bear $BBW, will do well
Reported earnings this morning
Beats top/bottom and raises
+17% in PM but we'll see what the call says
I'm sound asleep knowing my teddy bear company, Build-a-Bear $BBW, will do well
Reported earnings this morning
Beats top/bottom and raises
+17% in PM but we'll see what the call says
Have a look below for the key points and link to the report.
cedargrovecapital.substack.com/p/special-si...
Have a look below for the key points and link to the report.
cedargrovecapital.substack.com/p/special-si...
You can tell not much thought or diligence has gone into them. Perhaps it's the market that makes people think making money is easy but that shouldn't make your process any less stringent or in-depth.
You can tell not much thought or diligence has gone into them. Perhaps it's the market that makes people think making money is easy but that shouldn't make your process any less stringent or in-depth.
$DKS has rallied hard and the trade is up 6.7% right now
Assuming deal close, annualized return at ~12%
Check it out below for free
www.cedargrovecm.com/p/m-and-a-ar...
$DKS has rallied hard and the trade is up 6.7% right now
Assuming deal close, annualized return at ~12%
Check it out below for free
www.cedargrovecm.com/p/m-and-a-ar...
Well above even what I thought it was going to be (550 vs 350)
Call will be important but a great win since we published the idea earlier this year
Our $LQDA pitch is back to where it was trading back in early Jan though nothing has materially changed besides not being able to sell Yutrepia sooner
May launch and all else equal, a path to 2x still there
www.cedargrovecm.com/p/yutrepia-l...
Well above even what I thought it was going to be (550 vs 350)
Call will be important but a great win since we published the idea earlier this year
- Retailer operating in a recession-resilient industry
- Has grown topline >20% a Q for the last 11 Qs
Have a look below for key points and link
cedargrovecapital.substack.com/p/a-double-h...
- Retailer operating in a recession-resilient industry
- Has grown topline >20% a Q for the last 11 Qs
Have a look below for key points and link
cedargrovecapital.substack.com/p/a-double-h...
Very pleased with the results this morning. Stock up +16%
Appreciate all of those who read/supported our work
www.cedargrovecm.com/p/a-bunch-of...
Very pleased with the results this morning. Stock up +16%
Appreciate all of those who read/supported our work
www.cedargrovecm.com/p/a-bunch-of...
Our outline should help fellow investors transfer this thought process to other areas they may be looking at.
www.cedargrovecm.com/p/when-misun...
Our outline should help fellow investors transfer this thought process to other areas they may be looking at.
www.cedargrovecm.com/p/when-misun...
Inbound container volume fell 7.9% in June from a year before, after a 6.6% drop in May.
The declines more than wiped out a nearly 10% increase tied to inventory front-loading in April, and left the second quarter down 1.8% from a year earlier.
Inbound container volume fell 7.9% in June from a year before, after a 6.6% drop in May.
The declines more than wiped out a nearly 10% increase tied to inventory front-loading in April, and left the second quarter down 1.8% from a year earlier.